<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065112</url>
  </required_header>
  <id_info>
    <org_study_id>297733</org_study_id>
    <nct_id>NCT05065112</nct_id>
  </id_info>
  <brief_title>Individualised Mapping in Persistent AF Ablation</brief_title>
  <acronym>IMAGE AF</acronym>
  <official_title>Individualised MApping-Guided Ablation to Improve Outcomes in pErsistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Brompton &amp; Harefield NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical randomised trial to compare strategies for ablation in persistent and&#xD;
      long-standing persistent atrial fibrillation comprising of two arms: pulmonary veins&#xD;
      isolation (PVI) only and PVI + individualised mapping-guided ablation (Cartofinder, Biosense&#xD;
      Webster Inc.)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from atrial arrhythmia</measure>
    <time_frame>12 monts</time_frame>
    <description>Freedom from any atrial arrhythmia without the use of antiarrhythmic drugs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from atrial fibrillation without the use of antiarrhythmic drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation burden reduction</measure>
    <time_frame>12 months</time_frame>
    <description>Reduction of the atrial fibrillation burden by 75% compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute atrial fibrillation burden</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute atrial fibrillation burden after a single, first-time ablative procedure guided by individualised mapping vs. standard approach.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>PVI only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will undergo only standard pulmonary veins isolation with radiofrequency (RF) energy to treat their AF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PVI + IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will undergo standard wide area circumferential pulmonary veins isolation along with radiofrequency energy and additional RF ablation guided by individualised mapping with Cartofinder to treat their AF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary veins isolation + Cartofinder-guided ablation</intervention_name>
    <description>The individualised mapping with Cartofinder intends to identify areas with the repetitive atrial activation patterns which are targeted with focal or linear ablation anchored on at least one end in an anatomical or electrical barrier.</description>
    <arm_group_label>PVI + IM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary veins isolation</intervention_name>
    <description>Wide area circumferential pulmonary veins isolation</description>
    <arm_group_label>PVI only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years old&#xD;
&#xD;
          2. Signed informed consent.&#xD;
&#xD;
          3. Scheduled to undergo a clinically indicated, first-time catheter ablation procedure&#xD;
             for the treatment of persistent atrial fibrillation.&#xD;
&#xD;
          4. In atrial fibrillation at the time of the index procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Paroxysmal atrial fibrillation.&#xD;
&#xD;
          2. Previous ablation procedure for atrial fibrillation.&#xD;
&#xD;
          3. Left ventricular ejection fraction &lt; 45%&#xD;
&#xD;
          4. Obesity with BMI &gt; 35 kg/m2&#xD;
&#xD;
          5. Congenital heart disease.&#xD;
&#xD;
          6. Previous cardiac surgery with atriotomy.&#xD;
&#xD;
          7. Previous left atrial appendage closure/ligation.&#xD;
&#xD;
          8. Contraindications to systemic anticoagulation, catheter ablation, and/or general&#xD;
             anaesthesia.&#xD;
&#xD;
          9. Pregnancy&#xD;
&#xD;
         10. Current enrolment in a study evaluating another device or drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vias Markides, MD, FESC</last_name>
    <role>Study Director</role>
    <affiliation>Royal Brompton Hospital, London, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vias Markides, MD, FESC</last_name>
    <phone>020 7352 8121</phone>
    <email>v.markides@imperial.ac.uk</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>persistent atrial fibrillation</keyword>
  <keyword>catheter ablation</keyword>
  <keyword>individualized mapping</keyword>
  <keyword>focal activity</keyword>
  <keyword>rotational activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

